Saikosaponin-d suppresses the expression of cyclooxygenase-2through the phospho-signal transducer and activator of transcription 3/hypoxia-inducible factor-1α pathway in hepatocellular carcinoma cells

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2556-2562

  He, Shuixiang ^a   Lu, Guifang ^a   Hou, Helei ^b   Zhao, Zhenjun ^c   Zhu, Zhanfang ^d   Lu, Xinlan ^a   Chen, Jinghong ^d   Wang, Zhilun ^d  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Qindao Municipal Medical Group   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Hepatocellular carcinoma cell; Hypoxia inducible factor 1 ; Saikosaponin d; Signal transducer and activator of transcription 3

Indexed keywords

CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SAIKOSAPONIN D; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; OLEANOLIC ACID; PTGS2 PROTEIN, HUMAN; SAIKOSAPONIN; SAPONIN; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CELL HYPOXIA; CELL NUCLEUS; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CELL SURVIVAL; CYTOPLASM; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION; GENE REPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; LIVER CELL CARCINOMA; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING;

APIACEAE; BUPLEURUM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SHAPE; CYCLOOXYGENASE 2; HEP G2 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; OLEANOLIC ACID; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SAPONINS; STAT3 TRANSCRIPTION FACTOR;

EID: 84907202609     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2574     Document Type: Article

References (38)

1. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A and Castagnetta LA: Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NY Acad Sci 963: 3-20, 2002.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. El Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763, 2008.
4. Lu CN, Yuan ZG, Zhang XL, et al: Saikosaponin a and its epimer saikosaponin d exhibit anti inflammatory activity by suppressing activation of NF κB signaling pathway. Int Immunopharmacol 14: 121-126, 2012.
5. Hattori T, Nishimura H, Kase Y and Takeda S: Saireito and saikosaponin D prevent urinary protein excretion via glucocorticoid receptor in adrenalectomized WKY rats with heterologous phase anti GBM nephritis. Nephron Physiol 109: 19-27, 2008.
6. Fan J, Li X, Li P, et al: Saikosaponin d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol 85: 189-195, 2007.
7. Dang S, Wang B, Cheng Y, Song P, Liu Z and Li Z: Inhibitory effects of saikosaponin d on CCl4 induced hepatic fibrogenesis in rats. World J Gastroenterol 13: 557-563, 2007.
8. Kato M, Pu M and Isobe K, et al: Characterization of the immunoregulatory action of saikosaponin d. Cell Immunol 159: 15-25, 1994.
9. Wong VK, Zhou H, Cheung SS, Li T and Liu L: Mechanistic study of saikosaponin d (Ssd) on suppression of murine T lymphocyte activation. J Cell Biochem 107: 303-315, 2009.
10. Man S, Gao W, Zhang Y, Huang L and Liu C: Chemical study and medical application of saponins as anti cancer agents. Fitoterapia 81: 703-714, 2010.
11. Bachran C, Bachran S, Sutherland M, Bachran D and Fuchs H: Saponins in tumor therapy. Mini Rev Med Chem 8: 575-584, 2008.
12. Hsu Y, Kuo P and Lin C: The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non small cell lung cancer A549 cells. Life Sci 75: 1231-1242, 2004.
13. Hsu Y, Kuo P, Chiang L and Lin C: Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett 213: 213-221, 2004.
14. He SX, Luo JY, Zhao G, et al: Effect of saikosaponins d on cyclooxygenase 2 expression of human hepatocellular carcinoma cell line smmc 7721. Zhonghua Gan Zang Bing Za Zhi 14: 712-714, 2006 (In Chinese).
15. Ristimaki A: Cyclooxygenase 2: from inflammation to carcinogenesis. Novartis Found Symp 256: 215-269, 2004.
16. Bin W, He W, Feng Z, et al: Prognostic relevance of cyclooxygenase 2 (COX 2) expression in Chinese patients with prostate cancer. Acta Histochem 113: 131-136, 2011.
17. Matsubayashi H, Infante JR, Winter JM, et al: Tumor COX 2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 6: 1569-1575, 2007.
18. Mascaux C, Martin B, Paesmans M, et al: Has Cox 2 a prognostic role in non small cell lung cancer? A systematic review of the literature with meta analysis of the survival results. Br J Cancer 95: 139-145, 2006.
19. Harris RE: Cyclooxygenase 2 (COX 2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009.
20. Harris RE, Beebe Donk J and Alshafie GA: Cancer chemoprevention by cyclooxygenase 2 (COX 2) blockade: results of case control studies. Subcell Biochem 42: 193-212, 2007.
21. Bae SH, Jung ES, Park YM, et al: Expression of cyclooxygenase 2 (COX 2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX 2 inhibitor, NS 398. Clin Cancer Res 7: 1410-1418, 2001.
22. Cha YI and DuBois RN: NSAIDs and cancer prevention: Targets downstream of COX 2. Annu Rev Med 58: 239-252, 2007.
23. Yuan Y, Hilliard G, Ferguson T and Millhorn DE: Cobalt inhibits the interaction between hypoxia inducible factor alpha and von Hippel Lindau protein by direct binding to hypoxia inducible factor alpha. J Biol Chem 278: 15911-15916, 2003.
24. Xu Q, Briggs J, Park S, et al: Targeting Stat3 blocks both HIF 1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24 (36): 5552-5560, 2005.
25. Yu JH, Kim KH and Kim H: Suppression of IL 1beta expression by the Jak 2 inhibitor AG490 in cerulein stimulated pancreatic acinar cells. Biochem Pharmacol 72: 1555-1562, 2006.
26. Bu S, Xu J and Sun J: Effect of saikosaponin d on up regulating GR mRNA expression and inhibiting cell growth in human leukemia cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 20: 350-352, 2000. (In Chinese).
27. Tsai YJ, Chen I, Horng LY and Wu RT: Induction of differentiation in rat C6 glioma cells with Saikosaponins. Phytother Res 16: 117-121, 2002.
28. Wang B, Dai Z, Wang X, et al: Saikosaponin d increases the radiosensitivity of smmc 7721 hepatocellular carcinoma cells by adjusting the g0/g1 and g2/m checkpoints of the cell cycle. BMC Complement Altern Med 13: 263, 2013.
29. Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912, 2008.
30. Bartkowiak K, Riethdorf S and Pantel K: The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis. Cancer Microenviron 5: 59-72, 2012.
31. Ke Q and Costa M: Hypoxia inducible factor 1 (HIF 1). Mol Pharmacol 70: 1469-1480, 2006.
32. Zheng S, Chen X, Yin X and Zhang B: Prognostic significance of HIF 1α expression in hepatocellular carcinoma: A meta analysis. PLoS One 8: e65753, 2013.
33. Csiki I, Yanagisawa K, Haruki N, et al: Thioredoxin 1 modulates transcription of cyclooxygenase 2 via hypoxia inducible factor 1alpha in non small cell lung cancer. Cancer Res 66: 143-150, 2006.
34. Kaidi A, Qualtrough D, Williams AC and Paraskeva C: Direct transcriptional up regulation of cyclooxygenase 2 by hypoxia inducible factor (HIF) 1 promotes colorectal tumor cell survival and enhances HIF 1 transcriptional activity during hypoxia. Cancer Res 66: 6683-6691, 2006.
35. Dai C, Gao Q, Qiu S, et al: Hypoxia inducible factor 1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 9: 418, 2009.
36. Jung JE, Lee HG, Cho IH, et al: STAT3 is a potential modulator of HIF 1 mediated VEGF expression in human renal carcinoma cells. FASEB J 19: 1296-1298, 2005.
37. Wang M, Tan J, Coffey A, Fehrenbacher J, Weil BR and Meldrum DR: Signal transducer and activator of transcription 3 stimulated hypoxia inducible factor 1 alpha mediates estrogen receptor alpha induced mesenchymal stem cell vascular endothelial growth factor production. J Thorac Cardiovasc Surg 138: 163-171, 2009.
38. Cascio S, D'Andrea A, Ferla R, et al: miR 20b modulates VEGF expression by targeting HIF 1 alpha and STAT3 in MCF 7 breast cancer cells. J Cell Physiol 224: 242-249, 2010.